Brelovitug

布瑞罗韦塔单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameBrelovitug
Drug Alias NameBJT-778
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-HBsAg
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis D, ChronicHepatitis C, ChronicHepatitis B, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[26] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesMirum Pharmaceuticals IncBluejay Therapeutics Inc
Inactive CompaniesLonza
Active IndicationsHepatitis D, ChronicHepatitis C, ChronicHepatitis B, Chronic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A